VEOPOZ (pozelimab-bbfg) injection

VEOPOZ is a prescription medicine used to treat CHAPLE. FDA approved pozelimab-bbfg (brand name VEOPOZ) is not (yet) registered or available in India but on request Indian patient can buy VEOPOZ at the lowest price.

VEOPOZ-pozelimab-bbfg-Price-Delhi-India
VEOPOZ (pozelimab-bbfg) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

VEOPOZ (pozelimab-bbfg) injection

Pozelimab, is a recombinant monoclonal antibody used for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease.

VEOPOZ is a complement inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.

Pozelimab, sold under the brand name Veopoz, is a recombinant monoclonal antibody used for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease. Pozelimab is a complement inhibitor. It is produced using recombinant DNA technology in Chinese hamster ovary cells.

The most common adverse reactions include upper respiratory tract infections, fractures, hives, and alopecia.

Pozelimab was approved for medical use in the United States in August 2023. It is the first FDA-approved treatment for CHAPLE disease. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

VEOPOZ (pozelimab-bbfg) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2023

—————-
Current Indication: Treat of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease
—————-
Marketed By: Regeneron
—————-
Approval Date: : 2023
—————-
Active ingredient: pozelimab-bbfg
—————-
Inactive ingredients: arginine hydrochloride, histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sucrose, and Water for Injection
—————-

Capsules: 1 mg and 5 mg.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.